Nurix Therapeutics (NRIX) Stock: Roche Signs $2.3B Blood Cancer Drug Deal

TLDR

• Roche has entered an exclusive licensing and collaboration deal with Nurix Therapeutics worth up to $2.3 billion
• Nurix will receive $700 million upfront, with the rest tied to development, regulatory, and sales milestones
• The deal centres on bexobrutideg, a blood cancer drug targeting chronic lymphocytic leukaemia (CLL)
• Development costs will be split 60% Roche / 40% Nurix, with U.S. profits and losses split equally
• Phase III clinical trials are set to begin this summer, with the deal expected to close in Q3 2026

---

Nurix Therapeutics (NRIX) stock was in focus on Monday after Roche announced an exclusive licensing and collaboration agreement to develop bexobrutideg, a blood cancer drug.

Nurix Therapeutics, Inc., NRIX

The deal is valued at up to $2.3 billion. NRIX stock fell around 4% on the news.

Bexobrutideg is an investigational tyrosine kinase degrader. Rather than blocking disease-causing proteins, it eliminates them entirely — a different mechanism from older treatments in the space.

The drug is being developed to treat chronic lymphocytic leukaemia, a form of blood cancer, along with other blood-related diseases.

Nurix will collect $700 million upfront. The rest of the potential $2.3 billion is tied to hitting specific development, regulatory, and commercial milestones.

That’s a meaningful cash injection for a clinical-stage biotech. Milestones like these can take years to materialise — but the upfront payment alone is substantial.

On the cost side, Roche will cover 60% of development expenses. Nurix carries the remaining 40%.

In the United States, the two companies will co-commercialise the drug and split profits and losses equally. Outside the U.S., Roche takes the lead and pays Nurix royalties.

Phase III Trials This Summer

Phase III trials for bexobrutideg in CLL are planned to kick off this summer. That’s a key next step for a drug that, if approved, would compete in a crowded but high-value blood cancer market.

Roche’s chief medical officer Levi Garraway said the company believes bexobrutideg “could represent a major leap forward in the fight against complex blood cancers and other diseases.”

The deal is expected to officially close in Q3 2026.

What This Means for Nurix

For a company of Nurix’s size, landing a partner like Roche is a major development. The $700 million upfront gives Nurix a strong financial runway while sharing the clinical risk.

The equal U.S. profit split also means Nurix stands to benefit directly if bexobrutideg reaches commercialisation.

Phase III data will be the next major catalyst to watch. CLL is one of the most common forms of adult leukaemia, which means the commercial opportunity — if the drug works — is large.

The deal was announced Monday morning. NRIX was down roughly 4% in early trading.